🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Zsuzsanna Nagy

Harvard University

ORCID: 0000-0001-7425-3762

Also affiliated with Dana-Farber Cancer Institute

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer”.

Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2975

N/A

0.907DataRank · unranked

35 citations

Agostina Nardone, Douglas Russo, Zsuzsanna Nagy, Capucine Héraud, Albert Grinshpun +26 more

Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Cancer Research(2023)10.1158/0008-5472.can-23-1711

N/A

0.596DataRank · unranked

15 citations

Yingtian Xie, Shira Sherman, Zsuzsanna Nagy, Douglas Russo, Tara Akhshi +36 more

Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer

npj Breast Cancer(2024)10.1038/s41523-024-00647-1

N/A

0.241DataRank · unranked

4 citations

Douglas Russo, Wen Ma, Ana Verma, Francisco Hermida-Prado, Shira Sherman +13 more

ESR1 fusions and therapeutic resistance in metastatic breast cancer

Frontiers in Oncology(2023)10.3389/fonc.2022.1037531

N/A

0DataRank · unranked

37 citations

Rinath Jeselsohn, Zsuzsanna Nagy